Skip to main content

Advertisement

SpringerLink
Log in

Perspectives on cardiac allograft vasculopathy

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Allograft arteriopathy, the slowly progressive, diffuse, atherosclerosis noted often after heart transplant, and also called chronic rejection, is the most common cause of late cardiac graft failure and patient death. The process is multifactorial, rooted in both immune and nonimmune factors that can be coupled to passenger atherosclerosis moved with the donor heart, as well as initially nondiseased endothelium. Great insight has emerged from experimental models and intravascular ultrasound study of patients, but treatments are still crude and produce less than optimal results. Nonetheless, it has been demonstrated that diltiazem, pravastatin, ganciclovir, newer immunosuppressive agents, and photophoresis may be helpful. In the future, better control of the allograft immunologic response will likely be the key to attenuating development of this form of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hosenpud JD, Novick RJ, Breen TJ, et al.: The registry of the International Society for Heart and Lung Transplantation: twelfth official report. J Heart Lung Transplant 1995, 14: 805–815.

    PubMed  CAS  Google Scholar 

  2. Smith JA, Ribakove GH, Hunt SA et al.: Heart retransplantation: the 25-year experience at a single institution. J Heart Lung Transplant 1995, 14: 832–839.

    PubMed  CAS  Google Scholar 

  3. Azuma H, Tilney NL: Immune and nonimmune mechanisms of chronic rejection of kidney allografts. J Heart Lung Transplant 1995, 14: S136-S142.

    PubMed  CAS  Google Scholar 

  4. Billingham ME: Histopathology of graft coronary disease. J Heart Lung Transplant 1992, 11: S38-S44.

    PubMed  CAS  Google Scholar 

  5. Gao SZ, Alderman EL, Schroeder JS, et al.: Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findings. J Am Coll Cardiol 1988, 12: 334–340.

    PubMed  CAS  Google Scholar 

  6. Johnson JA, Kobashigawa JA: Quantitative analysis of transplant coronary artery disease with use of intracoronary ultrasound. J Heart Lung Transplant 1995, 14: S198-S202.

    PubMed  CAS  Google Scholar 

  7. Kapadia SR, Ziada K, L’Lallier PL, et al.: Intravascular ultrasound imaging after cardiac transplantation: advantage of multivessel imaging. J Heart Lung Transplant 2000, 19: 167–172.

    Article  PubMed  CAS  Google Scholar 

  8. Ziada KM, Kapadia SR, Tuzcu EM, Nissen SE: The current status of intravascular coronary ultrasound imaging. Curr Probl Cardiol 1999, 24: 541–566.

    Article  PubMed  CAS  Google Scholar 

  9. Tuzcu EM, De Franco AC, Goormastic M, et al.: Dichotomous pattern of coronary atherosclerosis 1 to 9 years aftger transplantation. Insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol 1996, 27: 839–846.

    Article  PubMed  CAS  Google Scholar 

  10. Mehra MR, Ventura HO, Stapleton DD, et al.: The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: A paradigm shift. J Heart Lung Transplant 1995, 14: S207-S211.

    PubMed  CAS  Google Scholar 

  11. Valantine H: Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995, 14: S234-S237.

    PubMed  CAS  Google Scholar 

  12. Miller L, Kobashigawa J, Valantine H, et al.: The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant 1995, 14: S227-S234.

    PubMed  CAS  Google Scholar 

  13. Hauptman PJ, Nakagawa T, Tanaka H, et al.: Acute rejection: Culprit or coincidence in the pathogenesis of cardiac graft vascular disease? J Heart Lung Transplant 1995, 14: S173-S180.

    PubMed  CAS  Google Scholar 

  14. Kobashigawa JA, Miller L, Yeung A, et al.: Does acute rejection correlate with the development of transplant coronary artery disease? a multicenter study using intravascular ultrasound. J Heart Lung Transplant 1995, 14: S221-S226.

    PubMed  CAS  Google Scholar 

  15. Rose EA, Smith CR, Petrossian GA, et al.: Hemoimmune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery 1989, 106: 203–207.

    PubMed  CAS  Google Scholar 

  16. Wheeler CH, Collins A, Dunn MJ, et al.: Characterization of endothelial antigens associated with transplant-associated coronary artery disease. J Heart Lung Transplant 1995, 14: S188-S197.

    PubMed  CAS  Google Scholar 

  17. Hammond EH, Yowell RL, Price GD et al.: Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 1992, 11: S111-S119.

    PubMed  CAS  Google Scholar 

  18. Dunn MJ, Crisp SJ, Rose ML, et al.: Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992, 339: 1566–1570.

    Article  PubMed  CAS  Google Scholar 

  19. Faulk WP, Labarrere CA, Nelson VR, et al.: Hemostasis, fibrinolysis, and natural anticoagulation in transplant vascular sclerosis. J Heart Lung Transplant 1995, 14: S158-S164.

    PubMed  CAS  Google Scholar 

  20. Labarrere CA, Pitts D, Nelson DR, et al.: Vascular tissue plasminogen activator and the development of coronary artery disease in heart transplant recipients. N Engl J Med 1995, 333: 1111–1116.

    Article  PubMed  CAS  Google Scholar 

  21. Grattan MT, Moreno-Cabral CE, Starnes VA, et al.: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261: 3561–3566.

    Article  PubMed  CAS  Google Scholar 

  22. Hauptman PJ, Davis SF, Miller L, et al.: The role of nonimmune risk factors in the development and progression of graft arteriosclerosis: preliminary insights from a multicenter intravascular ultrasound study. J Heart Lung Transplant 1995, 14: S238-S242.

    PubMed  CAS  Google Scholar 

  23. Johnson MR: Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992, 11: S124-S132.

    PubMed  CAS  Google Scholar 

  24. Day JD, Rayburn BK, Gaudin PB, et al.: Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995, 14: S142-S149.

    PubMed  CAS  Google Scholar 

  25. Ballantyne CM, Mainolf EA, Young JB, et al.: Relationship of increased levels of circulating intercellular adhesion molecules after heart transplantation to rejection: human HLA mismatch and survival. J Heart Lung Transplant 1995, 13: 597–603.

    Google Scholar 

  26. Winters G, Kendall TJ, Radio SJ, et al.: Post-transplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Lung Transplant 1990, 9: 364–371.

    CAS  Google Scholar 

  27. Dodet B, Plotkin S: Infection and atherosclerosis. Am Heart J 1999, 138(5:2): s417-s418.

    Article  Google Scholar 

  28. Mayer E, Jacobsen D, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996, 27: 517–521.

    Article  PubMed  CAS  Google Scholar 

  29. Gupta A, Moustapha A, Jacobsen D, et al.: High homocysteine, low folate, and low vitamin B6 concentrations: Prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998, 65: 544–550.

    Article  PubMed  CAS  Google Scholar 

  30. Valantine H, Gao S, Menon S, et al.: Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis: a post-hoc analysis of a randomized placebo controlled study. Circulation 1999, 6100(1): 61–66.

    Google Scholar 

  31. Gao SZ, Schroeder JS, Alderman EL, et al.: Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation 1989, 80(Suppl III): III-100–III-105.

    CAS  Google Scholar 

  32. Smart F, Ballantyne CM, Cocanougher B, et al.: Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol 1991, 67: 243–247.

    Article  PubMed  CAS  Google Scholar 

  33. Spes CH, Klauss V, Muddra HAH, et al.: Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and intravascular ultrasound. Circulation 1999, 100: 509–515.

    PubMed  CAS  Google Scholar 

  34. Fang JC, Rocco T, Jarahs J, et al.: Noninvasive assessment of transplant associated arterial sclerosis. Am Heart J 1998, 135: 980–987.

    Article  PubMed  CAS  Google Scholar 

  35. Costanzo MR, Naftel DC, Pritzkermor, et al.: Heart transplant CAD detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998, 17: 744–753.

    PubMed  CAS  Google Scholar 

  36. Schroeder JS, Gao SZ, Alderman EL, et al.: A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med 1993, 328: 164–170.

    Article  PubMed  CAS  Google Scholar 

  37. Yusuf S, Lonn E: Anti-ischemic effects of ACE inhibitors: a review of current clinical trials. Eur Heart J 1998, 19: J36-J4.

    Article  PubMed  CAS  Google Scholar 

  38. The Heart Outcomes Prevention Evaluation Investigators: Effects of an angiotensin converting enzyme inhibitor, rampiril on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Eng J Med 2000, 342(3): 145–153.

    Article  Google Scholar 

  39. Kobashigawa JA, Katznelson A, Laks H et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333: 621–627.

    Article  PubMed  CAS  Google Scholar 

  40. Cutts JL, Scallen TJ, Watson J, et al.: Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989, 139: 550–557.

    Article  PubMed  CAS  Google Scholar 

  41. Foegh ML: Angiopeptin: A treatment for accelerated myointimal hyperplasia? J Heart Lung Transplant 1992, 11: S28-S31.

    PubMed  CAS  Google Scholar 

  42. Wahlers T, Mugge A, Opelt P, et al.: Preventive treatment of coronary vasculopathy in heart transplantation by inhibition of smooth muscle cell proliferation with angiopeptin. J Heart Lung Transplant 1995, 14: 143–150.

    PubMed  CAS  Google Scholar 

  43. Halle AA, DiSciascio G, Messin EK, et al.: Coronary angioplasty, atherectomy, and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995, 26: 120–128.

    Article  PubMed  Google Scholar 

  44. Razzouk AJ, Chinnock RE, Dearani J, et al.: Cardiac retransplantation for graft vasculopathy in children: should we continue to do it? Arch Surg 1998, 133: 881–885.

    Article  PubMed  CAS  Google Scholar 

  45. Young JB: Allograft vasculopathy: Diagnosing the nemesis of heart transplantation. Circulation 1999, 100: 458–460.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Department of Cardiology (Desk F-25), The Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    James B. Young MD

Authors
  1. James B. Young MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Young, J.B. Perspectives on cardiac allograft vasculopathy. Curr Atheroscler Rep 2, 259–271 (2000). https://doi.org/10.1007/s11883-000-0028-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-000-0028-x

Keywords

Search

Navigation